Galmed Pharmaceuticals Ltd (GLMD)

[UKdude]

Saw one similar to this a couple weeks ago run to north of $40.... This could go wild after opening bell.


GLTA

[crudeoil24]

Man-o-man, how high will this go today. Maybe 25+. These low floaters can run hard on solid news.

[TheFinalCD]

right back to 21.20's

GLMD

[crudeoil24]

Yup, in the 21's now

[TheFinalCD]

looking for $20 break after dip in the 17's

GLMD

[crudeoil24]

Huge surge in PM. GLMD > 21.51

[crudeoil24]

NEWS > Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol™, an oral, once-daily, liver-targeted SCD1 modulator, for the treatment of non-alcoholic steatohepatitis (NASH), announced top-line, 52-week results from the global Phase 2b ARREST study. In the ARREST study, patients underwent MRS and biopsy at baseline and week 52, which were centrally read, blinded to treatment allocation. The primary endpoint of the study was the change from baseline to end of study in liver triglycerides ratio as measured by MRS (Aramchol 600mg vs. placebo). Secondary endpoints, demonstrated through biopsy, included fibrosis improvement by at least one stage or more without worsening of NASH (defined by an increase of inflammation and or ballooning) and NASH resolution (defined by ballooning score 0 and inflammation score 0-1 at termination) without worsening of fibrosis. Other secondary endpoints included improvement (2 points or more) in NASH activity index, as measured by NAS or SAF, without worsening fibrosis and change in baseline to week 52/termination in ALT (U/L).

[noretreat]

Congrats to all here on the success!

[DewDiligence]

In my experience, making people wait until the next day to get the results is neither bullish nor bearish. I’ve seen it go both ways.

p.s. I have no position in GLMD, but it’s a 10% weighting in my SI charity portfolio.

[Inoviorulez]

Id be careful, they might have mixed results. Lots of time they try to spin the data with CC and presentation. if the results were good they could have just released a PR

[DewDiligence]

Results of phase-2b ARREST study tomorrow—CC at 8am ET:

https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-to-host-conference-call-to-discuss-top-line-52-week-results-from-the-global-phase-2b-arrest-study-300664375.html

[DewDiligence]

GLMD 1Q18 results—cash=$21.4M (counting $5.9M raised in April PP with BVF):

https://finance.yahoo.com/news/galmed-pharmaceuticals-provides-business-reports-110000240.html

The phase-2b ARREST study in NASH is still expected to read out in Jun 2018.

[DewDiligence]

GLMD +2% on registered-direct sale of 1M units @$6.00; each unit consists of 1 share and 1 warrant exercisable @$15 with an expiration of 1 year:

https://finance.yahoo.com/news/galmed-pharmaceuticals-announces-pricing-6-110000480.html

Yesterday’s closing price was $5.00, so the unit price of $6.00 is a pretty good deal for the company considering that the warrants are way out of the money.

[DewDiligence]

$35M ATM with Stifel—part of $150M shelf:

https://www.sec.gov/Archives/edgar/data/1595353/000114420418016920/tv489501_f3.htm

[DewDiligence]

The 2017 20-F (similar to Form 10-K for a foreign firm) has been filed:

https://www.sec.gov/Archives/edgar/data/1595353/000114420418014234/tv487506_20f.htm

[DewDiligence]

GLMD 4Q17 financials—12/31/17 cash=$19.0M:

https://www.sec.gov/Archives/edgar/data/1595353/000114420418014235/tv488278_ex99-1.htm

[aristotelisonassis]

break $5 and we are going nuts.

[DewDiligence]

GLMD -47% on failure of ARRIVE study in HIV/NAFLD: #msg-138540528.

[aristotelisonassis]

$5 soon

[aristotelisonassis]

volume!

[aristotelisonassis]

in here. very cheap. long!

[DewDiligence]

G. Yarom Medical Research owned a 27.3% equity stake as of 12/31/17:

https://www.sec.gov/Archives/edgar/data/1595353/000114420418004035/tv483844_sc13ga.htm

[Sampson001]

I'm up fairly well here, hoping for some positive results soon !!!

[DewDiligence]

There's a lot of anticipation regarding the NASH data to be released from two studies during the current quarter.

[noretreat]

stock is flying! found out about at the showcase 2 years ago.

[DewDiligence]

GLMD—Latest corporate slides:

https://www.sec.gov/Archives/edgar/data/1595353/000114420418000341/tv482490_ex99-1.htm

[DewDiligence]

GLMD had $19.0M of cash at 12/31/17 thanks to ATM sales during December (at relatively high prices):

https://www.sec.gov/Archives/edgar/data/1595353/000114420418000046/tv482405_ex99-1.htm

Galmed Pharmaceuticals…today announced it raised approximately $11.6 million in gross proceeds during December 2017 under the Company’s at-the-market (“ATM”) programs. The Company issued 1,368,667 ordinary shares under its former and existing ATM programs during December 2017 at an average sale price of $8.45 per share.

…Based on preliminary unaudited financial information, as of December 31, 2017, Galmed has cash and cash equivalents and marketable securities of approximately $19.0 million.

This is more than enough cash to carry GLMD to the data readout of the phase-2/3 ARREST trial in NASH, expected in 1Q18.

[puravida]

Dew I've been looking into the NAFLD/NASH arena too while I agree with you on the ENTA long hold I'm surprised you haven't nibbled at this. is it the cash position? the lower than expected funds raised at the end of summer? or are you more cautious of the mechanism behind the science? I do wish this co had more cash position IMO

[DewDiligence]

GLMD’s pro forma cash=$10.1M—including $1.1M raised via the ATM since 9/30/17:

https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-reports-third-quarter-2017-financial-results-and-provides-business-update-300551897.html

[DewDiligence]

No GLMD position; I'm long ENTA and keenly watching the NASH arena.

[Sampson001]

Seems to be a lot of accumulation as of late.....results are due in early 2018. I'm loaded, RU ?

[DewDiligence]

GLMD -15%/AH on sale of 381K shares @$7.10 in registered direct offering (of which insiders are buying 49K shares):

http://www.prnewswire.com/news-releases/galmed-pharmaceuticals-announces-pricing-of-offering-of-ordinary-shares-to-existing-investors-and-members-of-the-board-of-directors-300499533.html

The selloff in AH trading is presumably due to the fact that the company was able to raise only $2.7M (gross proceeds) from this offering. They need more.

[Sampson001]

The news is finally leaking out.....they presented impressive information last month at the Nash event in Holland. People are just coming around to this. GLMD is a very small company, so it takes a while for anything good to get in the ears of people. There will be a buy out before years end. G/l to all

[DewDiligence]

No news that I'm aware of.

[aintitahoot]

Stock has been perking up a bit, may be nothing of substance but still a very quiet board.

[Sampson001]

This is going to be a very big weekend coming up for GLMD. Big presentation in Holland.....watch for alot of band wagon buying after next weekend !!!!

[DewDiligence]

GLMD had only $12.2M net current assets at 12/31/16:

https://www.sec.gov/Archives/edgar/data/1595353/000114420417016148/v462263_20f.htm#f_002

[Sampson001]

Currently above the 2o, 50 and 100 day moving average. Me thinks there will be a little run here. Results due in June of 2017. If this is positive, we will see 15 - 17 bucks per share

[Sampson001]

Earnings report Monday am !!!

[noretreat]

This stock should be headed significantly higher in 2017. It is on my "buy the dips" list.

[biotechnician]

Major NASH news from BLRX

Pre-clinical results obtained in animal models of liver impairment suggest that BL-1220 has strong hepato-protective effects. Collectively, the data demonstrate that BL-1220 is able to restore liver function. This technology could be directed toward rapid regeneration of normal liver in both acute and chronic conditions of liver injury.

Philip Serlin, Chief Financial and Operating Officer of BioLineRx, said, "In August this year, we in-licensed the first compound under our multi-year strategic partnership with Novartis, a novel drug candidate for controlling liver fibrosis through modulation of the immune system. Today, we are pleased to announce the second compound under the Novartis collaboration, also for the treatment of liver pathologies. Both of these projects fit our strategic focus on the immunology space. We continue to work closely with Novartis to identify cutting-edge, novel therapies and we expect to bring additional promising projects to the collaboration by the end of the year."

[Logger007]

New life..

[DewDiligence]

GLMD on Nasdaq trades <$200K worth of stock on an average day.

[Sampson001]

Why didn;t this trade for the first half ?

[DewDiligence]

1Q16 PR/CC leave questions re liquidity/cash burn: #msg-122681999.

[Sampson001]

Just read an article stating that Biotech's are lagging and to get ready for them to roll....do we count as a BIOTECH ?

[Sampson001]

Thank you for the link to the financials from GLMD....$23 mill is more than what I read they had, I did read they'll be good till mid 2017 ? ...There should be a completed study of phase 2 by then. I think its called "Arrest" and that should be positive. A nice S/P jump due to those results would be a good time to do what ever they need to do to then increase their cash. I see you've got 90,000 plus posts...certainly don't have the time to read what you've posted to gauge your knowledge, I'm pretty sure yours FAR exceeds mine...I'm just more of an occasional investor willing to make a gamble here and there....it just seemed to me that GLMD was one that in time would pay off. 2000 shares in 5 years I'm hoping will turn out as a fairly nice reward. Any guidance / knowledge you share will be most appreciated.

[DewDiligence]

I replied in #msg-121799257.

[Sampson001]

Not sure GLMD will have cash by then....they'll have to resort to some type of dilution to create more cash.....

[noretreat]

interesting...wish I'd been holding more (of course)

http://seekingalpha.com/news/3171773-gilead-takeout-nimbus-stokes-buying-nash-players?app=1&uprof=45#email_link